Research Topics
| Andrew M EvensSummaryAffiliation: Northwestern University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphomaAndrew M Evens
Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Br J Haematol 140:385-93. 2008..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival...
Treatment of Hodgkin lymphoma: the past, present, and futureAndrew M Evens
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Nat Clin Pract Oncol 5:543-56. 2008..Furthermore, continued clinical-trial involvement by oncologists and patients is imperative to further advance the field of HL...
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens
Lymphoma Program, Division of Hematology Oncology, and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Br J Haematol 141:676-80. 2008..g. 44% DLBCL vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017). These data demonstrate that HIF and the thioredoxin family are abnormally activated in lymphoma...- Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern eraAndrew M Evens
DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
J Clin Oncol 28:1038-46. 2010..In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes... - Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOPAndrew M Evens
DO, Division of Hematology Oncology, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
J Clin Oncol 28:1017-24. 2010..CONCLUSION The expression of HIF-1alpha protein is an important independent favorable prognostic factor for survival in patients with DLBCL treated with R-CHOP... - The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens
Lymphoma Program, Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
Clin Cancer Res 15:6462-71. 2009..Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation... - Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerAndrew M Evens
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Chicago, Illinois, IL 60611, USA
Curr Opin Oncol 16:576-80. 2004.... - G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisAndrew M Evens
Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Br J Haematol 137:545-52. 2007..0% and OS 91.3% (P = 0.46 and 0.67 respectively). Our experience suggests that ABVD may be safely and effectively administered at >99% dose-intensity without G-CSF support, regardless of the ANC... - Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapyAndrew M Evens
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Curr Oncol Rep 12:383-94. 2010..Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored... - Hodgkin lymphoma in older patients: an uncommon disease in need of studyAndrew M Evens
Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Oncology (Williston Park) 22:1369-79. 2008..Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL... - Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsA M Evens
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Ann Oncol 22:1170-80. 2011..Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined... - Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphomaAndrew M Evens
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Clin Lymphoma Myeloma 7:472-4. 2007..The patient subsequently underwent matched sibling reduced-intensity allogeneic transplantation and remains disease free. Further study examining denileukin diftitox in patients with relapsed/refractory ATLL is warranted... - Molecular etiology of mature T-cell non-Hodgkin's lymphomasAndrew M Evens
Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Front Biosci 8:d156-75. 2003..Future studies in T-cell NHL are likely to provide additional disease-specific chromosomal translocations and molecular alterations with important translational implications... - Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignanciesAndrew M Evens
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
Curr Treat Options Oncol 6:289-96. 2005..Various clinical trials studying MGd as a single agent and in combination with radiation and/or chemotherapy for the treatment of hematologic malignancies are ongoing... - Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett
MidWest Center for Health Services Research and Policy Studies, VA Chicago Healthcare System, Chicago, IL, USA
Blood 106:3343-7. 2005..Reinitiation of epoetin therapy among individuals could be considered if antierythropoietin antibodies are undetectable... - Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cellsAndrew M Evens
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
Blood 105:1265-73. 2005..These studies provide a rationale for clinical investigation of this novel redox-mediating agent in patients with multiple myeloma and related disorders... - PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsSavita Bhalla
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Clin Cancer Res 15:3354-65. 2009.... - Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
J Clin Oncol 27:1653-9. 2009.... - Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett
VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
Br J Haematol 135:642-50. 2006..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed... - Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcomeChadi Nabhan
Division of Hematology Oncology, Advocate Lutheran General Hospital, 1700 Luther Lane, Park Ridge, IL, USA
Br J Haematol 156:196-204. 2012..Prospective studies for very elderly NHL that incorporate geriatric tools, especially ADLs, are warranted... - All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphomaAmareshwar T K Singh
Division of Haematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Br J Haematol 150:158-69. 2010..In summary, incorporation of ATRA into ND enhanced the biological activity of this retinoid in cell culture models of MCL... - CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- diseaseKatalin Kelemen
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Am J Clin Pathol 130:166-77. 2008..In multivariate Cox regression analysis, CD23 status and leukemic-phase MCL were the most important factors predicting outcome... - Treatment of T-cell non-Hodgkin's lymphomaAndrew M Evens
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Curr Treat Options Oncol 5:289-303. 2004..Prospective multi-institution clinical trials are critically important to determine the most effective treatment regimens that will continue to improve cure rates in these aggressive, yet treatable and often curable, diseases... - Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculataShuo Yang
Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Clin Cancer Res 16:4755-68. 2010..Furthermore, it has been shown to inhibit cancer cell proliferation and induce apoptosis in leukemia and solid tumor cell lines... - Oxidative stress and apoptosis: a new treatment paradigm in cancerRyan H Engel
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Front Biosci 11:300-12. 2006..Continued research is needed to better understand the mechanisms and specific apoptotic pathways involved in ROS-induced cell death, as well as, to determine the most rationale and effective combination of redox-active agents... - Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphomaJeffrey J Raizer
Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Chicago, IL 60611, USA
Cancer 118:3743-8. 2012..Because methotrexate is an integral part of PCSNL treatment, the authors assessed the antitumor activity and safety of pemetrexed in recurrent PCNSL... - Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) projectJune M McKoy
Division of Geriatric Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E Chicago, Chicago, IL 60611, USA
Leuk Res 31:599-604. 2007.... - Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell linesAmareshwar T K Singh
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Anticancer Res 30:1131-6. 2010..We hypothesized that reactive oxygen species (ROS)-generating MGd results in low-level p53 expression, making cells more susceptible to oxidant stress... - Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy
Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 54:497-502. 2013..5 months (range: 3-22.5+ months). A phase II trial at the MTD is under way to better define the toxicity and effectiveness of this regimen... - The potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureAndrew M Evens
Department of Medicine, Divison of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA
Leuk Res 28:891-900. 2004..Continued study of As2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease... - Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) groupAndrew M Evens
Divison of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 18:481-9. 2005..The decrease in cases occurred coincident with these varied changes, although it is difficult to prove causality. PRCA is a rare, but important side effect of epoetin therapy... - Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphomaBrian C H Chiu
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
Cancer Causes Control 19:859-67. 2008.... - Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic optionsKevin A David
Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Curr Treat Options Oncol 8:352-74. 2007..Continued translational and collaborative prospective clinical research efforts are needed in order to continue to increase the survival rates for Hodgkin lymphoma and to lessen the toxicities associated with lymphoma-related therapy... - Sun exposure and non-Hodgkin lymphoma: a population-based, case-control studyLori K Soni
Department of Preventive Medicine, Northwestern University Medical School, Chicago, IL, United States
Eur J Cancer 43:2388-95. 2007..In conclusion, our data suggest that total hours of sun exposure is associated with a lower risk of NHL, and the inverse association is not modified by vitamin D intake, is stronger among farmer, and may vary by subtypes... - Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control studyHeather A Lankes
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
Cancer Causes Control 20:517-23. 2009..Results of few epidemiologic studies conducted thus far are inconsistent, and only one has examined the association by histologic subtype... - Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyondAndrew M Evens
Division of Hematology/Oncology, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Clin Lymphoma 5:S11-5. 2004..Radioimmunotherapy represents a safe and effective treatment modality for patients with NHL... - A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern eraAndrew M Evens
Division of Hematology Oncology, University of Massachusetts Medical School, Worcester, 01655, USA
Blood 119:692-5. 2012..04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001)... - Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemiaYi Hua Chen
Dept of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Am J Clin Pathol 136:289-99. 2011..Awareness of these features is important for early recognition and accurate diagnosis of patients with CD4-/CD8- γδ T-LGL leukemia... - The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaSavita Bhalla
Department of Medicine, Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
Blood 118:1052-61. 2011..Altogether, these findings show that the novel anti-MEK agent, AZD6244, induced apoptosis in DLBCL and that cell death was BIM-dependent... - T-cell non-Hodgkin lymphomaMujahid A Rizvi
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA
Blood 107:1255-64. 2006..Additional studies are required to learn more about the biology of these diseases, which may lead to more optimal and possibly targeted therapies... - The Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett
Jesse Brown VA Medical Center Mid West Center for Health Services and Policy Research, Chicago, Ill 60611, USA
JAMA 293:2131-40. 2005.... - Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependentAndrew M Evens
Departments of Medicine and Pathology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
Clin Cancer Res 10:1481-91. 2004..Moreover, we have identified a mechanism of cytotoxicity in dexamethasone-sensitive and -resistant myeloma cells induced by imexon that is caspase-8 dependent... - Burkitt's and Burkitt-like lymphomaAndrew M Evens
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA
Curr Treat Options Oncol 3:291-305. 2002..Clinical trials remain critical to determine the most effective treatment regimens that will continue to improve cure rates in this aggressive but treatable disease... - Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic optionsChristiane Querfeld
Section of Dermatology, University of Chicago, Chicago, Illinois, USA
Oncology (Williston Park) 24:574-87. 2010..Continued clinical trial involvement by oncologists and patients is imperative to improve the outcomes for this malignancy... - Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applicationsSairah Ahmed
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Leuk Lymphoma 51:1163-77. 2010..A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL... - Clinical characteristics of erythropoietin-associated pure red cell aplasiaKenneth R Carson
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
Best Pract Res Clin Haematol 18:467-72. 2005..Timely identification and treatment of this rare syndrome can prevent the development of severe red blood cell transfusion requirements and the potential complications of iron overload, which results from these transfusions... - Primary mediastinal large B-cell lymphoma in HIV: report of two casesKatalin Kelemen
Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E Huron Street, Feinberg 7 302, Chicago, IL, 60611, USA
J Hematop 2:45-9. 2009..The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up... - Targeting angiogenesis for the treatment of sarcomaLakshmi Balasubramanian
Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Curr Opin Oncol 18:354-9. 2006..SUMMARY: Preclinical mechanistic study and clinical trials are continuing in order to evaluate the therapeutic role and ultimately validate the efficacy of the varied anti-angiogenesis agents in soft tissue and bone sarcoma... - Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphomaBrian C H Chiu
Department of Health Studies, University of Chicago, 5841 South Maryland Avenue, MC 2007, Chicago, IL 60637, USA
Cancer Causes Control 22:1183-95. 2011..Few studies have evaluated the potential association between consumption of fruit and vegetables and non-Hodgkin lymphoma (NHL) by histologic subtype, and the results of these studies have been inconsistent... - T-cell non-Hogdkin's lymphomaAndrew M Evens
Department of Medicine, Division of Hematology/Oncology Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Cancer Treat Res 131:161-220. 2006 - Pure red-cell aplasia and epoetin therapyCharles L Bennett
MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
N Engl J Med 351:1403-8. 2004.... - TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiologyAndrew M Evens
Department of Internal Medicine--Oncology/Hematology, Lakeside VA, Chicago, IL 60611, USA
Transplantation 74:885-7. 2002..DISCUSSION: Our findings suggest a nonimmunological etiology for TTP/HUS in clopidogrel-treated transplant recipients. Furthermore, mechanistic focused laboratory studies can facilitate interpretation of case report findings... - Obesity and risk of non-Hodgkin lymphoma (United States)Brian C H Chiu
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
Cancer Causes Control 18:677-85. 2007.... - The challenges of epidemiologic research in non-Hodgkin lymphomaAndrew M Evens
JAMA 300:2059-61. 2008
Research Grants
- Targeting the Mitochondria to Treat Lymphoma and MyelomaAndrew Evens; Fiscal Year: 2007..These investigations will be significant, as they are expected to provide a new target for the treatment of hematologic malignancies and will advance the fundamental understanding of oxidative stress and apoptosis. ..